{"version":"1.0","type":"rich","provider_name":"Libert\u00e9 Actus","provider_url":"https:\/\/liberteactus.c-real.org","title":"Du rififi chez Sanofi","author_name":"Lydie Lymer","width":"480","height":"295","url":"https:\/\/liberteactus.c-real.org\/questions-sociales\/sante\/article\/du-rififi-chez-sanofi","html":"\u003Ch4 class='title'\u003E\u003Ca href='https:\/\/liberteactus.c-real.org\/questions-sociales\/sante\/article\/du-rififi-chez-sanofi'\u003EDu rififi chez Sanofi\u003C\/a\u003E\u003C\/h4\u003E\u003Cblockquote class='spip'\u003E\u003Cp\u003ELe 10 octobre, le journal \u003Ci\u003ELes \u00c9chos\u003C\/i\u003E rapportait que Sanofi vendrait Opella au fonds am\u00e9ricain CD&R pour plus de 15 milliards d\u2019euros. La filiale de sant\u00e9 grand public du g\u00e9ant pharmaceutique fran\u00e7ais produit entre autres le Doliprane, m\u00e9dicament le plus consomm\u00e9 en France.\u003C\/p\u003E\u003C\/blockquote\u003E\n"}